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Orr presented the Bureau's Quarterly
Report, which reviewed the appointment
of Michael A. Kelley as Director of the
Department of Consumer Affairs, and
the Department's task force recommen-
dations for the Bureau. Chief Orr also
reported that the Bureau stayed under
its budget again this year, which was
originally $659,000 but was reduced to
$554,843. The proposed 1988-89 budget
is considerably less than that amount.
Patricia Bustos will continue as Chair
of the Advisory Board until the next
meeting. Elections could not be held




Executive Officer: Lorie G. Rice
(916) 445-5014
The Board of Pharmacy grants
licenses and permits to pharmacists,
pharmacies, drug manufacturers, whole-
salers and sellers of hypodermic needles.
It regulates all sales of dangerous drugs,
controlled substances and poisons. To
enforce its regulations, the Board em-
ploys full-time inspectors who investi-
gate accusations and complaints received
by the Board. Investigations may be
conducted openly or covertly as the
situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized
by law to suspend or revoke licenses or
permits for a variety of reasons, includ-
ing professional misconduct and any acts
substantially related to the practice of
pharmacy.
The Board consists of ten members,
three of whom are public. The remaining
members are pharmacists, five of whom
must be active practitioners. All are
appointed for four-year terms.
MAJOR PROJECTS:
OAL Disapproves Proposed Regula-
tion. On December 17, 1987, the Board
resubmitted proposed regulatory section
1781.5 for the third time to the Office of
Administrative Law (OAL) for approval.
(See CRLR Vol. 8, No. 1 (Winter 1988)
p. 69 and Vol. 7, No. 2 (Spring 1987)
p. 64 for background information.) The
proposed regulation would provide an
exemption for certain manufacturers and
wholesalers of drugs from the general
requirement that a California licensed
pharmacist be present and in control of
the manufacturing or wholesaling prem-
ises. On January 14, OAL once again
disapproved the proposed regulation, on
grounds that it still does not satisfy the
clarity standard.
Public Hearing. On January 20, the
Board held a public hearing on two
proposed regulatory changes: an amend-
ment to section 1717(a), chapter 17,
Title 16 of the California Code of Regu-
lations, concerning reuse of clean con-
tainers in a licensed health facility for
non-liquid oral products; and section
1718.1, regarding the distribution of
drugs not bearing a manufacturer's ex-
piration date. (See CRLR Vol. 8, No. I
(Winter 1988) p. 69 for details on these
proposed regulations.)
The Board adopted both changes,
and has submitted the rulemaking file to
the OAL.
Proposed Continuing Education
Regulations. In the last two years, the
OAL has twice disapproved the Board's
proposed changes to its complex con-
tinuing education (CE) regulations. (See
CRLR Vol. 8, No. 1 (Winter 1988) pp.
68-69 for background information.)
According to the Board's Initial State-
ment of Reasons accompanying its most
recent proposed version, OAL's second
disapproval prompted the Board to
"evaluate its program and its effect-
iveness." In its statement, the Board
reviewed its bifurcated and rather con-
fusing CE regulations, and stated that it
is "concerned not only with the bureau-
cratic nature of its CE program, but
also believes that pharmacists as profes-
sionals should have more flexibility in
determining what program best meets
his/her needs, and that it should be the
responsibility of the profession to moni-
tor the quality of CE."
The statement explained that the
Board's CE regulations presently contain
two kinds of course designations:
"accredited" and "acceptable." A phar-
macist must obtain thirty hours of CE
every two years, of which fifteen must
be "accredited." Currently, there are
three systems for reviewing CE: (1) the
provider is accredited through the Ameri-
can College of Pharmaceutical Educa-
tion (ACPE); (2) the coursework is re-
viewed by the Board through its CE
Committee; or (3) there is no review at
all, as with "acceptable" courses.
In its evaluation, the Board deter-
mined that CE should be more accessible
to pharmacists; more emphasis should
be placed on the provider application
process; there should be only one cate-
gory of CE; and the standards of ACPE
should be incorporated as part of the
accreditation process.
Thus, the Board has proposed a new
set of CE regulations in chapter 17,
Title 16 of the California Code of Regu-
lations. Section 1732 is a definitional
section; the proposed amendments would
define the new terms that will be used in
the CE article, and delete those terms
no longer applicable. Section 1732.05
would designate the ACPE and the Ac-
creditation Evaluation Service of the
California Pharmacists Association as
accreditation agencies; establish criteria
for the designation of other organiza-
tions as accreditation agencies; and
impose certain requirements on the agen-
cies with respect to the CE providers
they recognize and accredit. Section
1732.05 also sets forth grounds upon
which the Board may revoke accredita-
tion agency designation.
Section 1732.1 lists requirements for
recognized CE providers, including regis-
tration with the Board and approval by
a Board-designated accreditation agency.
The section also describes the content
and quality of acceptable CE courses;
and requires providers to furnish certifi-
cates of completion to all enrollees with
specified information thereon, and main-
tain CE course attendance records.
Section 1732.2 would allow pharma-
cists to petition the Board for credit if
a CE course was taken from a non-
recognized provider, and would also
provide a mechanism for Board licensees
to obtain CE credit for courses approved
by the Board of Medical Quality Assur-
ance, the Board of Registered Nursing,
the Board of Podiatric Medicine, and
the Board of Dental Examiners.
Section 1732.3 would deem all course-
work offered by recognized providers
(who have been approved by an accredi-
tation agency) as approved for Califor-
nia pharmacists, unless the accreditation
agency has denied the course as a result
of an audit. This section would also
require the accreditation agencies to
review selected coursework offered by
its providers, and specifies the require-
ments and the factors to be considered
when auditing courses.
Section 1732.4 would require upon
written request that each recognized
provider submit materials to the accredi-
tation agency for review. Finally, sec-
tion 1732.7 would alldw providers to file
complaints with the Board against accred-
itation agencies; this section is deemed
necessary because the Board is proposing
that the accreditation agency both ap-
prove the provider and audit the course-
work.
The Board was scheduled to conduct
a public hearing on its proposed CE
regulations on April 6 in Los Angeles.
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Proposed Fee Increases. The Board
has also proposed to amend section 1749
of its regulations to increase its licensure
fees, as authorized by SB 79 (Chapter
657, Statutes of 1987), which became
effective on January 1, 1988. The pro-
posed regulations include (among others)
a fee increase for filing an application
for the pharmacist's examination ($155);
the pharmacist's licensure examination
($75); original certification of registra-
tion ($115); biennial renewal of a phar-
macist's license ($115); pharmacy permit
($340); renewal pharmacy permit ($175);
issuance and renewal of a wholesaler's
permit ($550); and issuance and renewal
of a hypodermic license ($90).
The Board was scheduled to hold a
public hearing on its proposed fee in-
creases on April 6 in Los Angeles.
LEGISLATION:
SB 2213 (Craven), introduced Feb-
ruary 17, would require any pharmacy
located outside California which ships,
mails, or delivers any controlled sub-
stances or dangerous drugs or devices
into California to register with the
Board, disclose specified information to
the Board, and meet certain other con-
ditions. SB 2213 is pending in the Senate
Business and Professions Committee; at
this writing, the bill is scheduled for
hearing on April 11.
SB 2731 (Campbell), introduced Feb-
ruary 19, would exempt from the defini-
tion of "manufacturer" a pharmacy
which compounds a drug for parenteral
therapy, pursuant to a prescription, for
delivery to another person licensed to
possess that drug. This bill would also
require a pharmacy which compounds a
drug for another pursuant to the above
provision to report that information to
the Board within thirty days of com-
mencing that compounding. SB 2731 is
also scheduled for an April 11 hearing
before the Senate Business and Profes-
sions Committee.
AB 513 (Hill), formerly AB 513
(Tucker), was amended on March 9,
and would also exempt from the defini-
tion of a "manufacturer" a pharmacy
compounding a drug for parenteral thera-
py, pursuant to a prescription, for de-
livery to another person licensed to
possess that drug. AB 513 was approved
by the Senate Business and Professions
Committee on March 15, and is pending
on the Senate floor at this writing.
AB 3578 (Moore), introduced Feb-
ruary 17, would allow licensed drug
wholesalers to sell hypodermic syringes
and needles without a permit. The bill
would also add licensee incompetence,
fraud, and deceit as grounds for disci-
pline by the Board, and would allow the
Board to recover its investigative and
prosecutorial costs from the licensee in
certain disciplinary cases, including at-
torneys' fees and costs attributable to
obtaining injunctive relief.
AB 3578 would also prohibit owners,
managers and administrators of a disci-
plined Pharmacy Board licensee from
holding certain ownership or manage-
ment positions with any licensee of the
Board; further, pharmacists put on pro-
bation by the Board would be prohibited
from serving as the pharmacist-in-charge
of a pharmacy. This bill is pending in
the Assembly Health Committee.
AB 4499 (Felando), introduced Feb-
ruary 19, would authorize a pharmacist
to substitute a generically equivalent
drug for a prescribed drug only if it is
listed as having a "Code A" by the
federal Food and Drug Administration;
if it has a "Code B," the pharmacist
must obtain authorization from the pre-
scriber prior to substitution. AB 4499 is
pending in the Assembly Health Com-
mittee.
AB 2683 (Hughes), as introduced in
August 1987, would have required any
person who sells, furnishes, or distributes
prophylactics in California to be licensed
by the Board. As amended on January
21, the bill would prohibit the manufac-
ture, packaging, sale, furnishing, or
distribution of prophylactics which fail
to conform to standards adopted by the
Department of Health Services, and
would require the Department to adopt
those standards. AB 2683 passed the
Assembly on January 27, and is pending
in the Senate Health and Human Ser-
vices Committee at this writing.
AB 44 (Calderon), AB 1953 (Filante),
AB 1238 (Moore), AB 1732 (Isenberg),
and SB 1534 (Keene) have all died in
committee. (See CRLR Vol. 7, No. 4
(Fall 1987) pp. 63-64 for details on these
bills.)
FUTURE MEETINGS:
May 24-25 in Sacramento.
POLYGRAPH EXAMINERS
BOARD
Executive Officer: Dia Goode
(916) 739-3855
The Polygraph Examiners Board
operates within the Department of Con-
sumer Affairs. The Board has authority
to issue new licenses and to regulate the
activities of an estimated 655 examiners
currently licensed in California under
Business and Professions Code section
9300 et seq. The Board has no juris-
diction over federally-employed poly-
graph examiners.
The Polygraph Examiners Board
consists of two industry representatives
and three public members, all appointed
to four-year terms. The Board has a
sunset date of January 1, 1990.
MAJOR PROJECTS:
Regulatory Changes. In January, the
Office of Administrative Law approved
the Board's adoption of sections 3472
and 3410 of chapter 34, Title 16 of the
California Code of Regulations. Section
3472 allows federal, state, and local gov-
ernment agencies to provide continuing
education with Board approval. Section
3410 (previously numbered as proposed
section 3842) defines certain "polygraph
records" which examiners are required
to retain for two years. (See CRLR Vol.
7, No. 4 (Fall 1987) p. 64 for back-
ground information.)
Pre-Employment Inquiry Seminar.
The Board had scheduled a seminar on
pre-employment inquiries for January.
(See CRLR Vol. 7, No. 4 (Fall 1987)
p. 64.) Due to a shortage of funds, the
Board postponed the seminar. It is now
scheduled to take place in conjunction
with the Board's next meeting; the date
is undecided.
Budget. Business and Professions
Code section 9321(b) appropriated
$50,000 in the form of a loan from the
General Fund to the Board. The statute
provides that the Board was to pay
$10,000 interest in 1986, and that the
balance was to be repaid in increments
of not less than $10,000 each fiscal year.
The appropriation also states that the
Board shall pay back the entire loan by
January 1, 1990, which is its sunset
date. Executive Officer Dia Goode re-
cently reported that the Board paid the
1986 $10,000 interest payment, but has
not been able to make any payments on
the balance.
The recent fee increase, effective Jan-
uary 1, 1988, will not be enough to
remedy the Board's fiscal crisis. The
Board anticipates only 90 new licensees
and 400 renewals this year. However,
the Board's budget problems may be
resolved through SB 2220 (see infra
LEGISLATION).
LEGISLATION:
SB 2219 (Dills), introduced Febru-
ary 17, would provide that if a poly-
graph license is renewed more than
thirty days after its expiration, the
licenseholder, as a condition precedent
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